drugset
drugset / Trial / NCT04520360

Bioavailability and Food Effect Study of 3 Types of Carisbamate

NCT04520360 ↗

Phase 1 Completed 33 enrolled SK Life Science, Inc. PRA Health Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to examine the relative bioavailability of three carisbamate formulations (Oral Suspension Type 1, Oral Suspension Type 2, and a 300 mg Oral Tablet) and to assess the effect of food on the oral bioavailability of the Oral Suspension Type 2 and the 300 mg Oral Tablet.

Timeline

Start
2020-08-27
Primary completion
2021-10-06
Completion
2021-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 300 mg Oral

Indications

No indication recorded.